Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02830880 · ClinicalTrials.gov registry record · Phase 2

FACBC Prostate Therapy Response

A Phase 2 study of Prostate Cancer, sponsored by Emory University.

Completed
Registry status
Phase 2
Development phase
7
Enrollment target
1
Study location

NCT02830880: Completed Phase 2 study of Prostate Cancer, sponsored by Emory University.

NCT02830880 is a Phase 2 study of Prostate Cancer that has completed, run by Emory University. The registered enrollment target is 7 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02830880, a Phase 2 study of Prostate Cancer, has completed, sponsored by Emory University.

COMPLETED
Registry status
Phase 2
Development phase
7 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess if using anti-1-amino-3-\[18F\]fluorocyclobutane-1-carboxylic acid (FACBC or fluciclovine) PET scan will be useful in determining if participants are responding to chemotherapy treatment. Investigators will enroll participants whose cancer has been treated with hormone therapy and now the cancer is not responding to the treatment (castration -resistant), and so therefore will be started on chemotherapy. Investigators aim to enroll thirty participants in this study.

Primary Outcome

Clinical response will be assessed with FACBC PET imaging. The same measurements of the lesions and background structures will be undertaken at baseline and post-therapy scan. The researchers utilized the following parameters to follow response to therapy: maximum standardized uptake value (SUVmax) of most intense lesion each of bone and node, sum and mean SUVmax of up to 5 index lesions for each of bone and node of most intense lesion each of bone and node of the 5 index lesions for each of bon

Conditions Studied

Prostate Cancer

Interventions

  • DRUG FACBC PET-CT
  • OTHER MRI, CT, or Bone Scan

Study Locations (1)

Georgia

  • Emory University Hospital - Atlanta

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2016-07
Est. Completion 2019-09-30
Phase Phase 2
Emory University

1,208 total trials

What the finished NCT02830880 record still lists

NCT02830880 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which FACBC PET-CT is the first listed.

NCT02830880 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT02830880 about?

NCT02830880 is a clinical study titled "FACBC Prostate Therapy Response". The purpose of this study is to assess if using anti-1-amino-3-\[18F\]fluorocyclobutane-1-carboxylic acid (FACBC or fluciclovine) PET scan will be useful in determining if participants are responding to chemotherapy treatment. Investigators will enroll participants whose cancer has been treated with...

What is the current status of trial NCT02830880?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2016-07. Estimated completion is 2019-09-30.

What conditions does trial NCT02830880 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT02830880?

The interventions under investigation include: FACBC PET-CT (DRUG), MRI, CT, or Bone Scan (OTHER).

Who is sponsoring clinical trial NCT02830880?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02830880 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02830880's enrollment target sits among peer trials

7 729th of 735 higher than 6 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02830880, the US trial registry maintained by the National Library of Medicine. NCT02830880 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.